STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Human cell"
DOI: 10.1007/s13577-021-00582-4
Abstract: Gefitinib is known as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) while an increasing number of patients with non-small cell lung cancer (NSCLC) are becoming resistant to EGFR-TKI. Therefore, innovative methods are urgently needed to… read more here.
Keywords: hcc827 cells; inhibitor; gefitinib; stat3 inhibitor ... See more keywords
Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway
Sign Up to like & getrecommendations! Published in 2017 at "Bioscience Reports"
DOI: 10.1042/bsr20160478
Abstract: Recent evidence supports a role for microRNA-223 (miR-223) in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) used… read more here.
Keywords: hcc827 cells; hcc827; erlotinib; expression ... See more keywords
Inhibiting FGFR by toadflax reverses erlotinib resistance in nonsmall cell lung cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001649
Abstract: This study aims to demonstrate the effect of toadflax (bufalin) on erlotinib resistance in nonsmall cell lung cancer (NSCLC) by inhibiting the fibroblast growth factor receptor (FGFR). The microfluidic mobility transferase and caliper mobility-shift assays… read more here.
Keywords: cancer; fgfr; erlotinib resistance; hcc827 cells ... See more keywords